Study on MEDI4736 for Patients with Completely Removed Non-Small Cell Lung Cancer

Inclusion Criteria

• Diagnosed with primary non-small cell lung cancer (NSCLC), excluding large-cell neuroendocrine carcinomas.
• Classified as Stage IB (tumor size ≥ 4cm), II, or IIIA after surgery.
• Complete surgical removal of the lung cancer, with no remaining visible disease.
• No prior chemotherapy before surgery, but post-surgery chemotherapy is allowed.
• No previous cancer treatments other than standard post-surgery chemotherapy.
• Patients with N2 disease who had post-surgery radiation are eligible if they meet timing criteria.
• Good overall health with an ECOG performance status of 0 or 1.
• Meet specific blood and organ function criteria.
• Willing and able to complete quality of life and other questionnaires.
• Must provide informed consent and be available for treatment and follow-up.
• Treatment to start within 2 days of being assigned to a group.

Exclusion Criteria

• History of other cancers, except for certain skin cancers or cancers treated with no recurrence for 5 years.
• Combination of small cell and non-small cell lung cancer, or certain other lung tumors.
• History of autoimmune diseases, except for controlled Grave's disease or psoriasis, and stable hypothyroidism.
• History of immune system deficiencies or organ transplants requiring immunosuppression.
• Recent live vaccines or severe reactions to immune therapies.
• Heart conditions that are untreated or uncontrolled.
• Current use of other investigational drugs or cancer therapies.
• Active infections or serious medical conditions that prevent following the study protocol.
• Pregnant or breastfeeding women, or those not using effective contraception.